Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study Meeting Abstract
| Authors: | Oh, D. Y.; Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; Melichar, B.; Siena, S.; Stroyakovskiy, D.; Fielding, A.; Ma, Y.; Puvvada, S. D.; Lee, J. Y. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1494 |
| End Page: | S1495 |
| Language: | English |
| ACCESSION: | WOS:001122475400077 |
| DOI: | 10.1016/j.annonc.2023.10.209 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 74MO -- Source: Wos |
